Moneycontrol PRO
Upcoming Event : LeapToUnicorn - mentoring, networking and fundraising for startups. Register now
you are here: HomeNewsBusiness

Now, a device to kill coronavirus: This Bengaluru manufacturer gets approval from FDA, EU

It has been proven to be 99.9 percent effective in neutralising the Spike-Protein or S-protein that are present in coronavirus.

July 28, 2020 / 10:21 AM IST

Scalene Hypercharge Corona Canon (Shycocan), a device with the ability to contain the spread of coronavirus, has received approvals from the US Food and Drug Administration (FDA) and the European Union (EU). It is developed by a Bengaluru-based organisation called De Scalene, News18 reported.

Shycocan is built like a small drum that can be fit into offices, schools, malls, hotels, airports, or any closed area for disinfecting surfaces. It is proven to be 99.9 percent effective in neutralising the Spike-Protein or S-protein that are present in coronavirus.

While it cannot cure an infected person, it is highly effective in containing the spread of the deadly virus, the report said.

The device floods a room or any indoor place with hundreds of electrons. So even if an infected individual were to walk into the room, these electrons would neutralise the potency of the virus present in aerosols while sneezing or coughing.

It can also neutralise the virus present on surfaces, thus bringing down transmission via air or surface.

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more

Speaking to News18, Dr. Rajah Vijay Kumar said that they have received clearance from the US FDA  under an enforcement directive for COVID-19 health emergencies. As for the EU, they have received the Conformite' Europeene or the certificate of conformity for which Shycocan was put through nearly 26 tests.

The tests include safety, efficacy, testing to determine whether the device has any harmful effects or if it interferes with the working of other devices. It also included tests to assess whether other devices deployed in any place would interfere with the performance of Shycocan.

According to officials, approval for manufacturing came in last week. Kumar also said that the cost and manufacturing will be depending on licence holders, adding that in India, about nine companies have shown interest in manufacturing Shycocan and three companies have entered into a licensing agreement, the report said.
Moneycontrol News
first published: Jul 27, 2020 06:07 pm